LANREOTIDE THERAPY in CARCINOID SYNDROME: PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY

George A. Fisher, Edward M. Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F. Pommier, Montaser Shaheen, Aaron I. Vinik

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.

Original languageEnglish (US)
Pages (from-to)243-255
Number of pages13
JournalEndocrine Practice
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Octreotide
Carcinoid Tumor
Placebos
Diarrhea
Neuroendocrine Tumors
Therapeutics
lanreotide
Somatostatin
Least-Squares Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

LANREOTIDE THERAPY in CARCINOID SYNDROME : PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY. / Fisher, George A.; Wolin, Edward M.; Liyanage, Nilani; Lowenthal, Susan Pitman; Mirakhur, Beloo; Pommier, Rodney F.; Shaheen, Montaser; Vinik, Aaron I.

In: Endocrine Practice, Vol. 24, No. 3, 01.03.2018, p. 243-255.

Research output: Contribution to journalArticle

Fisher, George A. ; Wolin, Edward M. ; Liyanage, Nilani ; Lowenthal, Susan Pitman ; Mirakhur, Beloo ; Pommier, Rodney F. ; Shaheen, Montaser ; Vinik, Aaron I. / LANREOTIDE THERAPY in CARCINOID SYNDROME : PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY. In: Endocrine Practice. 2018 ; Vol. 24, No. 3. pp. 243-255.
@article{db3f2cff11224c878a240103c09a3c23,
title = "LANREOTIDE THERAPY in CARCINOID SYNDROME: PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NA{\"I}VE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY",
abstract = "Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were na{\"i}ve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-na{\"i}ve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.",
author = "Fisher, {George A.} and Wolin, {Edward M.} and Nilani Liyanage and Lowenthal, {Susan Pitman} and Beloo Mirakhur and Pommier, {Rodney F.} and Montaser Shaheen and Vinik, {Aaron I.}",
year = "2018",
month = "3",
day = "1",
doi = "10.4158/EP172000.OR",
language = "English (US)",
volume = "24",
pages = "243--255",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "3",

}

TY - JOUR

T1 - LANREOTIDE THERAPY in CARCINOID SYNDROME

T2 - PROSPECTIVE ANALYSIS of PATIENT-REPORTED SYMPTOMS in PATIENTS RESPONSIVE to PRIOR OCTREOTIDE THERAPY and PATIENTS NAÏVE to SOMATOSTATIN ANALOGUE THERAPY in the ELECT PHASE 3 STUDY

AU - Fisher, George A.

AU - Wolin, Edward M.

AU - Liyanage, Nilani

AU - Lowenthal, Susan Pitman

AU - Mirakhur, Beloo

AU - Pommier, Rodney F.

AU - Shaheen, Montaser

AU - Vinik, Aaron I.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.

AB - Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). Methods: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks. Patients reported diarrhea and/or flushing symptom severity and frequency and short-acting SC octreotide rescue therapy daily using an Interactive Voice/Web Response System. To evaluate the efficacy of lanreotide compared with placebo, the novel primary endpoint of patient-determined use of SC octreotide rescue therapy for breakthrough symptoms was used as a surrogate for symptom control. Clinically meaningful patient-reported treatment benefit was examined using daily patient-reported symptoms of diarrhea and flushing. Results: Of the 115 randomized patients, 51 (n = 26 lanreotide, n = 25 placebo) were octreotide-naïve (de novo) and 64 (n = 33 lanreotide; n = 31 placebo) received prior octreotide. Lanreotide versus placebo patients had a lower mean percentage of days of SC octreotide rescue therapy in de novo and prior octreotide groups (least squares LS mean difference-19.1, P =.0477 and-6.9, P =.4332, respectively). The mean percentage of days with moderate/severe diarrhea and/or flushing was lower in lanreotide versus placebo patients in de novo and prior octreotide groups (LS mean difference-14.6, P =.0140 and-10.9, P =.0746, respectively). The transition from octreotide to lanreotide was generally well-tolerated. Conclusion: Improvement in CS symptoms occurred with lanreotide treatment, regardless of prior octreotide use.

UR - http://www.scopus.com/inward/record.url?scp=85044121266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044121266&partnerID=8YFLogxK

U2 - 10.4158/EP172000.OR

DO - 10.4158/EP172000.OR

M3 - Article

C2 - 29547049

AN - SCOPUS:85044121266

VL - 24

SP - 243

EP - 255

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 3

ER -